规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | Octreotide acetate, a long-acting synthetic analog of native somatostatin, inhibits growth hormone, glucagon, and insulin more potently. Octreotide-treated groups show a significant reduction in the tumor volume when compared with saline group. Octreotide-PPSG (1.4 mg/kg, i.p.) shows greater antitumor effect than Octreotide-soln (100 μg/kg, i.p.). Octreotide-treatments results in significant inhibitory effect on the expression levels of SSTR2 and SSTR5 in primary HCC-bearing rats compared with the saline group[3]. Octreotide can decrease the rate of postoperative complication after pancreatic resection by diminishing exocrine function of the pancreas. Prophylactic octreotide is not effective to inhibit the exocrine secretion of the remnant pancreas and does not decrease the incidence of pancreatic fistula after pancreaticoduodenectomy[4]. The prophylactic use of LAO (long-acting octreotide acetate) did not prevent the incidence or reduce the severity of diarrhea and had no notable impact on patient-reported bowel function or QoL(quality of life)[5]. Octreotide LAR (octreotide acetate) 20 mg shows significant efficacy in terms of objective response rate (PR + SD), biochemical and symptomatic control in patients with metastatic NETs (neuroendocrine tumors) of the GEP system pretreated and progressing on slow release lanreotide[6]. |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT00274170 | Migraine Headache | Phase 1 Phase 2 | Unknown | - | United States, Texas ... 展开 >> CR Darnall Army Medical Center Recruiting Ft. Hood, Texas, United States, 76544 收起 << |
NCT00616551 | Acromegaly | Phase 3 | Completed | - | Belarus ... 展开 >> Republican Centre for Medical Rehabilitation and Water-therapy Minsk, Belarus Hungary Semmelweis Egyetem Általános Orvostudományi Budapest, Hungary Romania Institute of Endocrinology "C. I. Parhon" Bucharest Bucharest, Romania Serbia Institute of Endocrinology, University Clinical Center Belgrade, Serbia Slovakia Fakultná Nemocnica s Poliklinkou Bratislava Bratislava, Slovakia Ukraine V.P. Komisarenko Institute of Endocrinology and Metabolism, AMS Ukraine Kiev, Ukraine 收起 << |
NCT00003057 | Colorectal Cancer ... 展开 >> Diarrhea 收起 << | Phase 3 | Completed | - | - |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
0.93mL 0.19mL 0.09mL |
4.63mL 0.93mL 0.46mL |
9.27mL 1.85mL 0.93mL |
CAS号 | 79517-01-4 |
分子式 | C51H70N10O12S2 |
分子量 | 1079.291 |
别名 | SMS 201-995 acetate |
运输 | 蓝冰 |
存储条件 |
In solvent -20°C:3-6个月-80°C:12个月 Pure form Inert atmosphere,Store in freezer, under -20°C |
溶解方案 |
DMSO: 250 mg/mL(231.63 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO H2O: 25 mg/mL(23.16 mM),配合低频超声助溶 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
动物实验配方 |